Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Stage

Acquired | Acquired

Valuation

$0000 

About Celenex

Celenex, a spinout of Nationwide Children's Hospital, is developing treatments for rare genetic diseases.

Celenex Headquarter Location

1275 Kinnear Rd

Columbus, Ohio, 43212,

United States

Latest Celenex News

Celenex takeout first of several expected Amicus gene therapy deals

Sep 24, 2018

Celenex takeout first of several expected Amicus gene therapy deals 9:34 AM PDF Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million in cash up front, plus milestones. More deals are on the way, Chairman and CEO John Crowley said on a conference call Sept. 20 to discuss the deal, with Amicus planning to in-license additional gene therapies in the coming months. Via Celenex, Amicus gains exclusive, worldwide rights to develop and... Read the full 402 word article User Sign in

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Celenex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Celenex is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.